[5] In neurology, Elan was focused on building upon its research and experience in the area of neuropathologies such as Alzheimer’s disease, where the company’s efforts included programs focused on small molecule inhibitors of beta secretase and gamma secretase, enzymes whose actions are thought to affect the accumulation of the amyloid plaques found in the brains of patients with Alzheimer’s disease.

Élan, in collaboration with Wyeth, conducted a Phase III clinical trial for bapineuzumab, an experimental humanized monoclonal antibody with a targeted indication of immunotherapeutic treatment of mild to moderate Alzheimer’s disease.

This humanized monoclonal antibody is designed and engineered to clear the neurotoxic beta-amyloid peptide, that accumulates in the brains of patients with Alzheimer’s disease.

Although initial results from an earlier Phase II clinical trial presented in July 2008 were inconclusive, Elan is hopeful that bapineuzumab will prove successful in the treatment of this disease.

Tysabri is a monoclonal antibody that inhibits immune cells from crossing blood vessel walls to reach various tissues, including the brain.